Europe Has Its Own Biotech Star as Argenx Soars on Trial Success

Argenx, a Belgium-based biopharmaceutical company, released positive Phase 3 trial results for its lead drug candidate. The company's stock price increased following the announcement. Argenx develops treatments in immunology and rare disease areas.

Next story